R113
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 106
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.440
- ALLOGRAFT_REJECTION+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- TNFA_SIGNALING_VIA_NFKB+0.400
- HYPOXIA+0.390
- INFLAMMATORY_RESPONSE+0.370
- COAGULATION+0.320
- ANGIOGENESIS+0.310
- TGF_BETA_SIGNALING+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.240
- PANCREAS_BETA_CELLS-0.200
- NOTCH_SIGNALING-0.090
- DNA_REPAIR-0.080
- PROTEIN_SECRETION-0.070
- UNFOLDED_PROTEIN_RESPONSE-0.070
- CHOLESTEROL_HOMEOSTASIS-0.060
- HEDGEHOG_SIGNALING-0.050
- UV_RESPONSE_DN+0.000
- MYOGENESIS+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02650 | — | cohortSQ1 | 0.876 |
| 2 | ERR2208908 | — | — | 0.851 |
| 3 | aMVAC.P_008_TURBT_S226 | — | — | 0.839 |
| 4 | EPT0509 | EPN | EPN Tumor | 0.834 |
| 5 | SRR10899973 | — | — | 0.827 |
| 6 | MDT-AP-2651 | Med | Medulloblastoma | 0.823 |
| 7 | TCGA-75-5126-01A-01R-1755-07 | — | cohortA1 | 0.821 |
| 8 | GSM6454748 | — | C | 0.818 |
| 9 | MNG736 | — | — | 0.815 |
| 10 | BS_J1AB8PMA | Med | Medulloblastoma | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |